Roche Holdings AG (RHHBY) announced promising results Wednesday from its phase 3 lidERA Breast Cancer study, and the numbers tell a pretty compelling story. The trial evaluated giredestrant as an adjuvant endocrine treatment for estrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer. If those medical terms make your eyes glaze over, here's the simple version: this drug could help a lot of people avoid cancer coming back.

The results, presented at the 2025 San Antonio Breast Cancer Symposium, showed that giredestrant is the first and only oral selective estrogen receptor degrader to demonstrate superior invasive disease-free survival in the adjuvant setting. This marks the second positive phase 3 readout for the drug, following earlier success in the metastatic setting with the evERA study.

The Numbers That Matter

At the pre-specified interim analysis, adjuvant giredestrant significantly reduced the risk of invasive disease recurrence or death by 30% compared with standard-of-care endocrine therapy. That's not a marginal improvement—it's substantial.

Here's what that looks like in practice: at three years, 92.4% of patients taking giredestrant were alive and free of invasive disease versus 89.6% in the standard treatment arm. The benefit held consistent across all clinically relevant subgroups, which is exactly what you want to see in a trial like this.

Overall survival data weren't mature yet at the time of this analysis, but researchers observed a clear positive trend. Follow-up will continue to the next analysis to capture those longer-term outcomes.

Giredestrant also achieved a 31% risk reduction in distant recurrence-free interval, another key secondary endpoint. And crucially, the drug was well tolerated with adverse events that were manageable and consistent with its known safety profile.

What Comes Next

According to reports, these results suggest giredestrant could become a new standard in adjuvant endocrine therapy. But there's still an open question about which patients might need add-on CDK4/6 inhibitors like Novartis AG's (NVS) Kisqali.

Roche Chief Medical Officer Levi Garraway explained it clearly: a 30% improvement in disease-free survival means patients are 30% less likely to experience a recurrence compared with standard care. That's the kind of straightforward benefit that matters to both doctors and patients.

The financial implications aren't small either. JPMorgan analysts previously estimated the adjuvant indication could generate about $5 billion in annual revenue if approved. That would make this a blockbuster by any measure, assuming regulatory approval comes through and the drug gains adoption in clinical practice.